Notably, CX3CR1+ monocytes in MS patients were less abundant than in healthy subjects and unaffected by MP pulse therapy (data not shown), which is also in line with the lower abundance of non-classical CD14+CD16++ monocytes in MS patients regardless of their treatment (Figure 2). This evidence concerns the gene CD14 and myeloid sarcoma.